Advertisement

Preventing Perinatal Transmission of HIV—Are We Doing Enough?

  • Lauri-Ann Van der Poel
  • Hermione Lyall
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 549)

Abstract

Without any intervention, an HIV positive mother has overall a 25%–30% chance of transmitting the virus to her baby. With combination antiretroviral therapy and avoidance of breast-feeding, it is possible to reduce the prenatal transmission rate to less than 1%. This review takes a look at the different risk factors in perinatal HIV transmission and the ways in which we may optimize circumstances for delivery of an uninfected child from an infected mother with particular reference to the United Kingdom and developed practice.

Keywords

Viral Load Human Immunodeficiency Virus Type Premature Delivery Perinatal Transmission Post Exposure Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eshleman, S.H., Mracna, M., Guay, L.A., Deseyve, M., Cunningham, S., Mirochnick, M. et al. (2002). Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (ffIVNET 012). AIDS 15(15), 1951–1957.CrossRefGoogle Scholar
  2. European Collaborative Study; Swiss Mother and Child HIV Cohort Study. (2000). Combination antiretroviral therapy and duration of pregnancy. AIDS 14(18), 2913–2920.CrossRefGoogle Scholar
  3. Ioannidis, J.P., Abrams, E.J., Ammann, A., Bulterys, M., Goedert, J.J., Gray, L. et al. (2001). Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J. Infect. Dis. 183(4), 539–545.PubMedCrossRefGoogle Scholar
  4. International Perinatal HIV Group. (2001). Duration of ruptured membranes and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies. AIDS 15(3), 357–368.CrossRefGoogle Scholar
  5. Larbalestier, N., Mullen, J., O’Shea, S., Cottam, F., Sabin, C., Chrystie, I. et al. (2003). Drug resistance is uncommon in pregnant women with low viral load taking zidovudine monotherapy to prevent perinatal HIV transmission. AIDS 17(18), 2665–2667.PubMedCrossRefGoogle Scholar
  6. Tuomala, R.E., Shapiro, D.E., Mofenson, L.M., Bryson, Y., Culnane, M., Hughes, M.D. et al. (2002). Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N. Engl. J. Med. 346(24), 1863–1870.PubMedCrossRefGoogle Scholar
  7. Tookey, P.A. and Masters, J. (2003). National study of HIV in pregnancy & childhood. J. Arch. Dis. Child. 88(Suppl 1), A54–A57.Google Scholar
  8. Wade, N.A., Birkhead, G.S., Warren, B.L., Charbonneau, T.T., French, P.T., Wang, L. et al. (1998). Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N. Engl. J. Med. 339(20), 1409–1414.PubMedCrossRefGoogle Scholar

Copyright information

© Science+Business Media New York 2004

Authors and Affiliations

  • Lauri-Ann Van der Poel
  • Hermione Lyall

There are no affiliations available

Personalised recommendations